All In Biotech

Drug Trial Radar · NCT05287503

Ambroxol as a Disease-modifying Treatment in GBA-PD

Ambroxol as a Disease-modifying Treatment to Reduce the Risk of Cognitive Impairment in GBA-associated Parkinson's Disease. A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2 Trial

Last checked: Nov 19, 2026Latest source record: Aug 14, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

65

Actual

Start

Mar 9, 2022

Primary completion

Dec 15, 2024

Study completion Dec 20, 2024

Sponsor

Lead sponsor
Fondazione I.R.C.C.S. Istituto Neurologico Carlo BestaAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
IRCCS National Neurological Institute "C. Mondino" Foundation; University of Campania Luigi Vanvitelli
First posted
Mar 18, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 21 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The present multicenter, randomized, double-blind, placebo-controlled clinical trial will investigate whether the prolonged administration of high-dose oral Ambroxol over 52 weeks is safe, tolerable, able to change Glucocerebrosidase enzyme activity and alpha-synuclein levels in the central nervous system and, ultimately, to reduce the progression of cognitive decline and motor disability in 60 individuals with Parkinson's disease with mutations of the glucocerebrosidase gene (GBA1; OMIM 606463). Participants will undergo clinical, biomarker blood and cerebrospinal fluid analysis, neuropsychological, neuroimaging assessment throughout the course of the study.

Conditions

  • Parkinson Disease
  • GBA Gene Mutation

Interventions

  • Ambroxol HydrochlorideDrug

    Drug Ambroxol hydrochloride 200 mg plus excipients. The manufacturing process of the 200 mg Ambroxol hydrochloride tablets will be performed by wet granulation, drying, mixing and compression to the target final weight.

  • PlaceboDrug

    Excipients

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline in Montreal Cognitive Assessment scoreTime frame: baseline and week 52
  2. Change from baseline in conversion rate from normal cognitive function (PD-N) to mild cognitive impairment (PD-MCI) and from PD-N or PD-MCI to Parkinson-Dementia (PD-D)Time frame: baseline and week 52

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Fondazione IRCCS Istituto Neurologico Carlo Besta

    Milan, Italy

  • University of Campania "Luigi Vanvitelli"

    Naples, Italy

  • IRCCS National Neurological Institute "C. Mondino" Foundation

    Pavia, Italy

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.